Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Dihedral - D2  (3D View)
Global Stoichiometry: Homo 4-mer - A4 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 157922.30 
• Atom Count: 11096 
• Residue Count: 1400 
• Unique protein chains: 1

1WOK

Crystal structure of catalytic domain of human poly(ADP-ribose) polymerase complexed with a quinoxaline-type inhibitor

• DOI: 10.2210/pdb1WOK/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli


• Deposited: 2004-08-20 Released: 2005-03-15 
• Deposition Author(s): Iwashita, A., Hattori, K., Yamamoto, H., Ishida, J., Kido, Y., Kamijo, K., Murano, K., Miyake, H., Kinoshita, T., Warizaya, M., Ohkubo, M., Matsuoka, N., Mutoh, S.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 3 Å
• R-Value Free: 0.288 
• R-Value Work: 0.233 

Literature

Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors.

Iwashita, A., Hattori, K., Yamamoto, H., Ishida, J., Kido, Y., Kamijo, K., Murano, K., Miyake, H., Kinoshita, T., Warizaya, M., Ohkubo, M., Matsuoka, N., Mutoh, S.

(2005) Febs Lett. 579: 1389-1393

• PubMed: 15733846 
• DOI: 10.1016/j.febslet.2005.01.036


• PubMed Abstract: 
  

Two classes of quinazolinone derivatives and quinoxaline derivatives were identified as potent and selective poly(ADP-ribose) polymerase-1 and 2 (PARP-1) and (PARP-2) inhibitors, respectively. In PARP enzyme assays using recombinant PARP-1 and PARP-2, quinazolinone derivatives displayed relatively high selectivity for PARP-1 and quinoxaline derivatives showed superior selectivity for PARP-2. SBDD analysis via a combination of X-ray structural study and homology modeling suggested distinct interactions of inhibitors with PARP-1 and PARP-2. These findings provide a new structural framework for the design of selective inhibitors for PARP-1 and PARP-2.

---

Organizational Affiliation: 

Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 2-1-6 Kashima, Osaka 532-8514, Japan. [e-mail]

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Poly [ADP-ribose] polymerase-1	A, B, C, D	350	Homo sapiens	Mutation(s): 0  Gene Names: PARP1 (ADPRT, PPOL) EC: 2.4.2.30
Find proteins for P09874 (Homo sapiens) Go to Gene View: PARP1 Go to UniProtKB:  P09874

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
CNQ	A, B, C, D	3-(4-CHLOROPHENYL)QUINOXALINE-5-CARBOXAMIDE 2-(4-CHLOROPHENYL)-5-QUINOXALINECARBOXAMIDE C15 H10 Cl N3 O FLYGLPYJEQPCFY-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
CNQ	IC50: 33 nM (100) BINDINGDB
CNQ	IC50: 33 nM PDBBIND

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 3 Å
• R-Value Free: 0.288 
• R-Value Work: 0.233 
• Space Group: P 1 2₁ 1

Unit Cell:

Length (Å)	Angle (°)
a = 90.050	α = 90.00
b = 77.080	β = 117.43
c = 113.720	γ = 90.00

Software Package:

Software Name	Purpose
CCP4	data scaling
AMoRE	phasing
CNX	refinement

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2004-08-20 
• Released Date: 2005-03-15 
• Deposition Author(s): Iwashita, A., Hattori, K., Yamamoto, H., Ishida, J., Kido, Y., Kamijo, K., Murano, K., Miyake, H., Kinoshita, T., Warizaya, M., Ohkubo, M., Matsuoka, N., Mutoh, S.

Revision History 

• Version 1.0: 2005-03-15
  Type: Initial release
• Version 1.1: 2008-04-30
  Type: Version format compliance
• Version 1.2: 2011-07-13
  Type: Version format compliance
• Version 1.3: 2017-10-11
  Type: Refinement description